S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
LON:AVO

Advanced Oncotherapy (AVO) Share Price, News & Analysis

Today's Range
N/A
50-Day Range
1.75
1.75
52-Week Range
N/A
Volume
200,000 shs
Average Volume
1.27 million shs
Market Capitalization
£9.50 million
P/E Ratio
N/A
Dividend Yield
5.49%
Price Target
N/A
AVO stock logo

About Advanced Oncotherapy Stock (LON:AVO)

Advanced Oncotherapy plc, together with its subsidiaries, engages in designing, assembling, and selling proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The company also engages in the management of healthcare related properties. It has operations in the United Kingdom, Switzerland, and the United States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy plc was founded in 1994 and is headquartered in London, the United Kingdom.

AVO Stock News Headlines

Advanced Oncotherapy Share Chat
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Advanced Oncotherapy PLC AVO
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Advanced Oncotherapy raises £2mln at a premium
Advanced Oncotherapy plc (AVO.L)
Hardman & Co Research: Advanced Oncotherapy (AVO): On the home straight
Advanced Oncotherapy : Result of AGM
See More Headlines
Receive AVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Advanced Oncotherapy and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
6/29/2020
Today
4/17/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
174
Year Founded
N/A

Profitability

Net Income
£-32,600,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
GBX 0.05 per share
Book Value
GBX 14 per share

Miscellaneous

Free Float
N/A
Market Cap
£9.49 million
Optionable
Not Optionable
Beta
0.09
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Michael Jeffrey Sinclair (Age 82)
    Executive Chairman
    Comp: $434.42k
  • Mr. Nicolas Serandour (Age 49)
    CEO & Executive Director
    Comp: $502.96k
  • Prof. Stephen Myers OBE (Age 78)
    Executive Director
    Comp: $397.72k
  • Mr. Ed Lee
    COO & President of Europe
  • Mr. Graham Pughe
    Senior Vice-President of Accounting
  • Ms. Berengere Pons-Chabord
    Senior Vice-President of Corporate Finance
  • Mr. David Navas
    Vice President of Investor and Public Relations
  • Ms. Bridget Biggar
    Director of Human Resources
  • Ms. Donatella Ungaro
    Managing Director of ADAM
  • Ms. Marina Giunta
    Head of Physics Group

AVO Stock Analysis - Frequently Asked Questions

How were Advanced Oncotherapy's earnings last quarter?

Advanced Oncotherapy plc (LON:AVO) posted its quarterly earnings results on Monday, June, 29th. The company reported ($9.83) earnings per share for the quarter, missing the consensus estimate of ($8.90) by $0.93.

What other stocks do shareholders of Advanced Oncotherapy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Advanced Oncotherapy investors own include UK Oil & Gas (UKOG), Oxford Biomedica (OXB), BMR Group (BMR), GW Pharmaceuticals (GWPH), Lancashire (LRE), Sirius Minerals (SXX), Renishaw (RSW), Scancell (SCLP) and Tullow Oil (TLW).

How do I buy shares of Advanced Oncotherapy?

Shares of AVO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:AVO) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners